Protocols

Based on available clinical trial data, adipose-derived stem cell therapy protocols vary significantly depending on the target condition and delivery method. However, specific dosing information from completed and ongoing trials is limited in the current evidence.

Administration Routes

Clinical trials have investigated several delivery methods:

Intravenous infusion (NCT04744051) using expanded autologous adipose-derived mesenchymal stem cells
Local injection for conditions such as Crohn's fistula (NCT01440699) and recto-vaginal fistula (NCT01548092)
Direct application for wound healing applications

Cell Processing

Most protocols involve:

Harvesting adipose tissue (typically via liposuction)
Processing to isolate stromal vascular fraction (SVF) or
Laboratory expansion to produce mesenchymal stem cells (MSCs)
Quality control testing before administration

Treatment Phases

The clinical trials identified represent Phase 1 and Phase 2 studies, indicating the therapy is still in early investigational stages. One completed Phase 1 trial (NCT01440699) examined allogenic adipose-derived stem cells for Crohn's fistula, while another Phase 1/2 trial (NCT01649687) investigated treatment for cerebellar ataxia.

Evidence Limitations

The current evidence does not provide specific details regarding:

Standardized cell doses or concentrations
Treatment frequency or intervals
Duration of therapy protocols
Patient selection criteria

Important Disclaimer: This information is for educational purposes only and describes investigational protocols from clinical research. This is not personalized medical advice. Adipose-derived stem cell therapy remains largely experimental, and treatment protocols should only be considered under proper medical supervision in approved clinical trials or where legally available. Always consult with qualified healthcare providers for medical decisions.

Adipose-Derived Stem Cell Therapy

Member access required